Denosumab tied to higher rates of hyper-, hypocalcaemia in cancer patients with bone metastasis
The incidence of both hypercalcaemia and hypocalcaemia in cancer patients with bone metastasis appears to be higher with denosumab as compared to zoledronic acid, a recent study has shown. Moreover, adequate supplementation with calcium helps lower the risk of hypocalcaemia.
Denosumab tied to higher rates of hyper-, hypocalcaemia in cancer patients with bone metastasis
15 Nov 2019